Resistance to novel antiandrogen therapies in metastatic castration-resistant prostate cancer
K Boudadi, ES Antonarakis - Clinical Medicine Insights …, 2016 - journals.sagepub.com
Despite the introduction of novel therapies that maximally decrease androgen-receptor (AR)
signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal …
signaling activity, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal …
[HTML][HTML] Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
AR-V7-expressing metastatic prostate cancer is an aggressive phenotype with poor
progression-free survival (PFS) and overall survival (OS). Preliminary evidence suggests …
progression-free survival (PFS) and overall survival (OS). Preliminary evidence suggests …
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis
B Benzon, SG Zhao, MC Haffner, M Takhar… - Prostate cancer and …, 2017 - nature.com
Background: B7-H3 (CD276), part of the B7 superfamily of immune checkpoint molecules,
has been shown to have an immunomodulatory role. Its regulation, receptor and mechanism …
has been shown to have an immunomodulatory role. Its regulation, receptor and mechanism …
Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical …
E Shenderov, K Boudadi, W Fu, H Wang… - The …, 2021 - Wiley Online Library
Background AR‐V7‐positive metastatic prostate cancer is a lethal phenotype with few
treatment options and poor survival. Methods The two‐cohort nonrandomized Phase 2 study …
treatment options and poor survival. Methods The two‐cohort nonrandomized Phase 2 study …
Multiple learning parameters differentially regulate olfactory generalization.
TA Cleland, VA Narla, K Boudadi - Behavioral neuroscience, 2009 - psycnet.apa.org
Sensory representations depend strongly on the descending regulation of perceptual
processing. Generalization among similar stimuli is a fundamental cognitive process that …
processing. Generalization among similar stimuli is a fundamental cognitive process that …
Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).
K Boudadi, DL Suzman, B Luber, H Wang, J Silberstein… - 2017 - ascopubs.org
5035 Background: ARV7+ mCRPC is an aggressive phenotype with a median PFS of 3-4
mo and OS of 7-9 mo. We hypothesized that ARV7+ tumors would be enriched for DNA …
mo and OS of 7-9 mo. We hypothesized that ARV7+ tumors would be enriched for DNA …
Nickel catalysts promoted with lanthanum for ethanol steam reforming: Influence of support and treatment on activity
K Boudadi, A Bellifa, C Márquez-Álvarez… - Applied Catalysis A …, 2021 - Elsevier
The effect of support nature on the catalytic performance of Ni-based catalysts for ethanol
steam reforming (ESR) was investigated. Nickel catalysts supported on lanthanum-modified …
steam reforming (ESR) was investigated. Nickel catalysts supported on lanthanum-modified …
Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer
Abstract Purpose Hedgehog (Hh) pathway signaling has been implicated in prostate cancer
tumorigenesis and metastatic development and may be upregulated even further in the …
tumorigenesis and metastatic development and may be upregulated even further in the …
Compensatory responses to age-related decline in odor quality acuity: cholinergic neuromodulation and olfactory enrichment
N Mandairon, ST Peace, K Boudadi, CE Boxhorn… - Neurobiology of …, 2011 - Elsevier
The perceptual differentiation of odors can be measured behaviorally using generalization
gradients. The steepness of these gradients defines a form of olfactory acuity for odor quality …
gradients. The steepness of these gradients defines a form of olfactory acuity for odor quality …
[HTML][HTML] Diffuse hypopigmentation followed by hyperpigmentation in an African American woman with hemangiopericytoma treated with dasatinib
K Boudadi, R Chugh - Journal of Clinical and Diagnostic Research …, 2014 - ncbi.nlm.nih.gov
Dasatinib is a second-generation multi-target tyrosine kinase inhibitor (TKI) that has activity
against many imatinib-resistant BCR-ABL mutant forms, Src, and c-Kit tyrosine kinases …
against many imatinib-resistant BCR-ABL mutant forms, Src, and c-Kit tyrosine kinases …